Company intelligence / Profile preview

Polyplants

Ownership: Private
Development stage: Commercial

Overview

Polyplants is a Swiss company specializing in the mass propagation and genetic improvement of coffee and cocoa plants. In 2024, it entered a strategic partnership with CATIE to expand the production and distribution of improved coffee and cocoa varieties across Central America and the Caribbean. The company leverages advanced tissue culture techniques to deliver high-performing planting material that supports sustainable agriculture. There are no clinical results as this is not a pharma or therapeutic company.

Modalities: Tissue culturePlant biotechnology
Industry: Agriculture & AgTech

Partnerships

CATIE (Tropical Agricultural Research and Higher Education Center), Costa Rica

Beyond the preview

Go deeper on Polyplants.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyplants.

Explore the full profile